Abstract
In this issue of Cancer Cell, Mohammad et al. describe LSD1, a histone demethylase, as a therapeutic target in SCLC with a unique epigenetic signature to predict drug sensitivity. Inhibition of LSD1 reduces cell proliferation and stem cell maintenance while promoting cell differentiation and reducing tumor growth in preclinical models.
Copyright © 2015 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage*
-
Benzoates / administration & dosage*
-
Cyclopropanes / administration & dosage*
-
DNA Methylation / drug effects*
-
Enzyme Inhibitors / administration & dosage*
-
Histone Demethylases / antagonists & inhibitors*
-
Humans
-
Lung Neoplasms / drug therapy*
-
Small Cell Lung Carcinoma / drug therapy*
Substances
-
Antineoplastic Agents
-
Benzoates
-
Cyclopropanes
-
Enzyme Inhibitors
-
Histone Demethylases